{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:31:03Z","timestamp":1786980663377,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation for Young Scientists of China","award":["82403824"],"award-info":[{"award-number":["82403824"]}]},{"name":"Natural Science Foundation for Young Scientists of Sichuan, China","award":["2025ZNSFSC1919"],"award-info":[{"award-number":["2025ZNSFSC1919"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2024M752235"],"award-info":[{"award-number":["2024M752235"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872489"],"award-info":[{"award-number":["81872489"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Science and Technology Program","award":["2023YFS0003"],"award-info":[{"award-number":["2023YFS0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"DOI":"10.1007\/s10456-025-10008-6","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:29:34Z","timestamp":1758198574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Xuejin","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diyuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeming","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbar A.","family":"Habaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"1","key":"10008_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TGP Gr\u00fcnewald","year":"2018","unstructured":"Gr\u00fcnewald TGP, Cidre-Aranaz F, Surdez D et al (2018) Ewing sarcoma. Nat Rev Dis Primers 4(1):5","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10008_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/pbc.23040","volume":"57","author":"M Stahl","year":"2011","unstructured":"Stahl M, Ranft A, Paulussen M et al (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57(4):549\u2013553","journal-title":"Pediatr Blood Cancer"},{"key":"10008_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081685","author":"SK Z\u00f6llner","year":"2021","unstructured":"Z\u00f6llner SK, Amatruda JF, Bauer S et al (2021) Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10081685","journal-title":"J Clin Med"},{"key":"10008_CR4","doi-asserted-by":"publisher","first-page":"6681741","DOI":"10.1155\/2021\/6681741","volume":"2021","author":"GC Stachelek","year":"2021","unstructured":"Stachelek GC, Ligon JA, Vogel J et al (2021) Predictors of recurrence and patterns of initial failure in localized Ewing sarcoma: a contemporary 20-year experience. Sarcoma 2021:6681741","journal-title":"Sarcoma"},{"issue":"27","key":"10008_CR5","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33(27):3036\u20133046","journal-title":"J Clin Oncol"},{"key":"10008_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164035","author":"H Gong","year":"2023","unstructured":"Gong H, Xue B, Ru J, Pei G, Li Y (2023) Targeted therapy for EWS-FLI1 in Ewing sarcoma. Cancers. https:\/\/doi.org\/10.3390\/cancers15164035","journal-title":"Cancers"},{"issue":"1","key":"10008_CR7","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","volume":"11","author":"M Martinez-Lage","year":"2020","unstructured":"Martinez-Lage M, Torres-Ruiz R, Puig-Serra P et al (2020) In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nat Commun 11(1):5060","journal-title":"Nat Commun"},{"issue":"7","key":"10008_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nm.1983","volume":"15","author":"HV Erkizan","year":"2009","unstructured":"Erkizan HV, Kong Y, Merchant M et al (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing\u2019s sarcoma. Nat Med 15(7):750\u2013756","journal-title":"Nat Med"},{"issue":"15_suppl","key":"10008_CR9","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1200\/JCO.2021.39.15_suppl.11500","volume":"39","author":"JA Ludwig","year":"2021","unstructured":"Ludwig JA, Federman NC, Anderson PM et al (2021) TK216 for relapsed\/refractory Ewing sarcoma: interim phase 1\/2 results. J Clin Oncol 39(15_suppl):11500\u201311500","journal-title":"J Clin Oncol"},{"issue":"17","key":"10008_CR10","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-14-0072","volume":"20","author":"S Sankar","year":"2014","unstructured":"Sankar S, Theisen ER, Bearss J et al (2014) Reversible LSD1 inhibition interferes with global EWS\/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res 20(17):4584\u20134597","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10008_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1593\/neo.101202","volume":"13","author":"PJ Grohar","year":"2011","unstructured":"Grohar PJ, Griffin LB, Yeung C et al (2011) Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 13(2):145\u2013153","journal-title":"Neoplasia"},{"issue":"4","key":"10008_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejca.2011.09.027","volume":"48","author":"S Baruchel","year":"2012","unstructured":"Baruchel S, Pappo A, Krailo M et al (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children\u2019s Oncology Group. Eur J Cancer 48(4):579\u2013585","journal-title":"Eur J Cancer"},{"issue":"31","key":"10008_CR13","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/JCO.24.00020","volume":"42","author":"PA Meyers","year":"2024","unstructured":"Meyers PA, Federman N, Daw N et al (2024) Open-label, multicenter, phase I\/II, first-in-human trial of TK216: a first-generation EWS::FLI1 fusion protein antagonist in Ewing sarcoma. J Clin Oncol 42(31):3725\u20133734","journal-title":"J Clin Oncol"},{"issue":"11","key":"10008_CR14","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18(11):1493\u20131501","journal-title":"Lancet Oncol"},{"issue":"4","key":"10008_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS et al (2020) Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol 21(4):541\u2013550","journal-title":"Lancet Oncol"},{"issue":"7","key":"10008_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133152","volume":"10","author":"X Huang","year":"2015","unstructured":"Huang X, Park H, Greene J et al (2015) IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PLoS ONE 10(7):e0133152","journal-title":"PLoS ONE"},{"issue":"11","key":"10008_CR17","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1002\/ijc.32743","volume":"146","author":"M Charan","year":"2020","unstructured":"Charan M, Dravid P, Cam M et al (2020) GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer 146(11):3184\u20133195","journal-title":"Int J Cancer"},{"issue":"15","key":"10008_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M et al (2015) Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33(15):1688\u20131696","journal-title":"J Clin Oncol"},{"issue":"15","key":"10008_CR19","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/JCO.2011.37.2359","volume":"30","author":"WD Tap","year":"2012","unstructured":"Tap WD, Demetri G, Barnette P et al (2012) Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 30(15):1849\u20131856","journal-title":"J Clin Oncol"},{"key":"10008_CR20","doi-asserted-by":"publisher","first-page":"1013359","DOI":"10.3389\/fonc.2023.1013359","volume":"13","author":"EDG Fleuren","year":"2023","unstructured":"Fleuren EDG, Vlenterie M, van der Graaf WTA (2023) Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma. Front Oncol 13:1013359","journal-title":"Front Oncol"},{"issue":"3","key":"10008_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S et al (2020) Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21(3):446\u2013455","journal-title":"Lancet Oncol"},{"issue":"12","key":"10008_CR22","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/s41416-023-02413-9","volume":"129","author":"F Duffaud","year":"2023","unstructured":"Duffaud F, Blay J-Y, Le Cesne A et al (2023) Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. Br J Cancer 129(12):1940\u20131948","journal-title":"Br J Cancer"},{"issue":"1","key":"10008_CR23","first-page":"53","volume":"4","author":"T Diana","year":"2013","unstructured":"Diana T, Nguyen SS (2013) Pazopanib: approval for soft-tissue sarcoma. J Adv Practitioner Oncol 4(1):53\u201357","journal-title":"J Adv Practitioner Oncol"},{"issue":"2","key":"10008_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tranon.2019.12.001","volume":"13","author":"N Aggerholm-Pedersen","year":"2020","unstructured":"Aggerholm-Pedersen N, Rossen P, Rose H, Safwat A (2020) Pazopanib in the treatment of bone sarcomas: clinical experience. Transl Oncol 13(2):295\u2013299","journal-title":"Transl Oncol"},{"key":"10008_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-019-00362-w","author":"A Tamura","year":"2019","unstructured":"Tamura A, Yamamoto N, Nino N et al (2019) Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma. Int Cancer Conf J. https:\/\/doi.org\/10.1007\/s13691-019-00362-w","journal-title":"Int Cancer Conf J"},{"issue":"18","key":"10008_CR26","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2169\/internalmedicine.9879-17","volume":"57","author":"Y Mori","year":"2018","unstructured":"Mori Y, Kinoshita S, Kanamori T et al (2018) The successful treatment of metastatic extraosseous Ewing sarcoma with pazopanib. Intern Med 57(18):2753\u20132757","journal-title":"Intern Med"},{"issue":"4","key":"10008_CR27","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R (2020) Cell phonedb: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc 15(4):1484\u20131506","journal-title":"Nat Protoc"},{"issue":"15","key":"10008_CR28","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1093\/nar\/gkab638","volume":"49","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Liu T, Hu X et al (2021) Cell call: integrating paired ligand-receptor and transcription factor activities for cell-cell communication. Nucleic Acids Res 49(15):8520\u20138534","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10008_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L et al (2021) Inference and analysis of cell-cell communication using cell chat. Nat Commun 12(1):1088","journal-title":"Nat Commun"},{"issue":"10","key":"10008_CR30","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/2767-9764.CRC-23-0027","volume":"3","author":"LL Visser","year":"2023","unstructured":"Visser LL, Bleijs M, Margaritis T, van de Wetering M, Holstege FCP, Clevers H (2023) Ewing sarcoma single-cell transcriptome analysis reveals functionally impaired antigen-presenting cells. Cancer Res Commun 3(10):2158\u20132169","journal-title":"Cancer Res Commun"},{"issue":"2","key":"10008_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH et al (2024) Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol 42(2):293\u2013304","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10008_CR32","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J et al (2019) Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods 16(12):1289\u20131296","journal-title":"Nat Methods"},{"issue":"1","key":"10008_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41423-023-01110-0","volume":"21","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Jiang H, Yang N et al (2024) Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment. Cell Mol Immunol 21(1):47\u201359","journal-title":"Cell Mol Immunol"},{"key":"10008_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129962","author":"ML S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez ML, Rodr\u00edguez FD, Cove\u00f1as R (2023) Neuropeptide Y peptide family and cancer: antitumor therapeutic strategies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24129962","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10008_CR35","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/0008-5472.CAN-04-2192","volume":"65","author":"J Kitlinska","year":"2005","unstructured":"Kitlinska J, Abe K, Kuo L et al (2005) Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 65(5):1719\u20131728","journal-title":"Cancer Res"},{"issue":"1","key":"10008_CR36","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1038\/s41467-022-29898-x","volume":"13","author":"C Lu","year":"2022","unstructured":"Lu C, Mahajan A, Hong S-H et al (2022) Hypoxia-activated neuropeptide Y\/Y5 receptor\/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma. Nat Commun 13(1):2323","journal-title":"Nat Commun"},{"issue":"4","key":"10008_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccell.2022.03.007","volume":"40","author":"J Reading","year":"2022","unstructured":"Reading J, Foster K, Joshi K, Chain B (2022) Tracking down tumor-specific T cells. Cancer Cell 40(4):351\u2013353","journal-title":"Cancer Cell"},{"key":"10008_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092245","author":"TG Ara\u00fajo","year":"2021","unstructured":"Ara\u00fajo TG, Mota STS, Ferreira HSV, Ribeiro MA, Goulart LR, Vecchi L (2021) Annexin A1 as a regulator of immune response in cancer. Cells. https:\/\/doi.org\/10.3390\/cells10092245","journal-title":"Cells"},{"issue":"36","key":"10008_CR39","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1038\/onc.2011.112","volume":"30","author":"Y Li","year":"2011","unstructured":"Li Y, Cai L, Wang H et al (2011) Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 30(36):3887\u20133899","journal-title":"Oncogene"},{"issue":"10\u201311","key":"10008_CR40","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S1567-5769(03)00133-4","volume":"3","author":"V Ferlazzo","year":"2003","unstructured":"Ferlazzo V, D\u2019Agostino P, Milano S et al (2003) Anti-inflammatory effects of annexin-1: stimulation of IL-10 release and inhibition of nitric oxide synthesis. Int Immunopharmacol 3(10\u201311):1363\u20131369","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10008_CR41","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1158\/2159-8290.CD-22-0196","volume":"12","author":"L Wu","year":"2022","unstructured":"Wu L, Wu W, Zhang J et al (2022) Natural coevolution of tumor and immunoenvironment in glioblastoma. Cancer Discov 12(12):2820\u20132837","journal-title":"Cancer Discov"},{"issue":"4","key":"10008_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062449","volume":"8","author":"H Weyd","year":"2013","unstructured":"Weyd H, Abeler-D\u00f6rner L, Linke B et al (2013) Annexin A1 on the surface of early apoptotic cells suppresses CD8+ T cell immunity. PLoS ONE 8(4):e62449","journal-title":"PLoS ONE"},{"issue":"1","key":"10008_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","volume":"10","author":"M Toulmonde","year":"2025","unstructured":"Toulmonde M, Gu\u00e9gan J-P, Spalato-Ceruso M et al (2025) Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab. Signal Transduct Target Ther 10(1):202","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10008_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W (2018) Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18(3):195\u2013203","journal-title":"Nat Rev Immunol"},{"key":"10008_CR45","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.3389\/fimmu.2018.03081","volume":"9","author":"M Georganaki","year":"2018","unstructured":"Georganaki M, van Hooren L, Dimberg A (2018) Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol 9:3081","journal-title":"Front Immunol"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-025-10008-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10456-025-10008-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-025-10008-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:07:55Z","timestamp":1763446075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10456-025-10008-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["10008"],"URL":"https:\/\/doi.org\/10.1007\/s10456-025-10008-6","relation":{},"ISSN":["1573-7209"],"issn-type":[{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were conducted in compliance with ethical guidelines and regulations in the West China Hospital, Sichuan University. The collection of clinical specimens was approved by the Ethics Committee on Biomedical Research, West China Hospital, Sichuan University. The research approval number is 2021-789. Written informed consent was obtained from the patient before specimen collection. All animal procedures were performed following the guidelines of the Animal Care and Use Committee of the Experimental Animal Research Center, Sichuan University. This study was conducted following the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and approved the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"50"}}